Core Viewpoint - Chuangli Medical (01858) has seen a stock price increase of over 3%, currently trading at 17.62 HKD with a transaction volume of 28.2853 million HKD, following the announcement of a strategic investment in a healthcare-focused fund [1] Group 1: Investment Details - The company announced a joint investment with Nanchang Defu Investment Consulting Partnership (Limited Partnership) and other partners in the Nanchang Defu Phase IV Equity Investment Fund Partnership (Limited Partnership) [1] - The fund primarily targets growth and mature stage enterprises/projects in the healthcare industry, aligning with the company's core business [1] - The company, as a limited partner, has invested 50 million RMB, representing 9.2105% of the fund's total shares [1] Group 2: Strategic Implications - This investment aligns with the company's strategic development direction and is expected to enhance its industrial layout [1] - The collaboration is anticipated to leverage the investment experience and resource advantages of the partners, promoting deep integration of industrial operations and capital management [1] - The goal is to create a virtuous cycle of collaborative development, thereby improving the company's core competitiveness and overall profitability, leading to sustainable, safe, healthy, and stable high-quality growth [1]

Company Overview - Spring Medical is located in Tongzhou District, Beijing, and focuses on the development and research of high-end orthopedic medical devices, with a diverse product range covering joint, spine, sports medicine, and trauma categories [1] - The company has obtained 124 medical device registration certificates and has independently developed several products that hold a unique advantage and leading position in the domestic market, enhancing its core competitiveness and industry influence [1] Financial Performance - As of September 30, Spring Medical reported a total of 7,998 shareholders, with an average of 21,800 circulating shares per shareholder [2] - For the period from January to September 2024, the company achieved a revenue of 508 million yuan, representing a year-on-year decrease of 35.84% [2] - The net profit attributable to shareholders was 61.15 million yuan, down 66.14% year-on-year [2] Market Activity - On August 12, Spring Medical's stock price increased by 5.34%, reaching 25.27 yuan per share, with a trading volume of 20.05 million yuan and a turnover rate of 0.28%, resulting in a total market capitalization of 9.693 billion yuan [1]

Group 1 - The core viewpoint of the news highlights the recent performance of Spring Medical, with a notable increase in stock price and trading volume on August 11, where the stock rose by 6.39% with a transaction amount of 91.98 million yuan [1] - On August 11, Spring Medical had a financing buy-in amount of 9.91 million yuan and a net financing buy of 599,100 yuan, indicating strong investor interest [1] - The total financing and securities balance for Spring Medical reached 38.27 million yuan, accounting for 0.55% of its market capitalization, which is above the 80th percentile of the past year, indicating a high level of financing activity [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company reported a revenue of 230 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 3.6%, and a net profit of 58.07 million yuan, which is a 5.2% increase compared to the previous year [2] - As of March 31, 2025, the number of shareholders increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [2] Group 3 - Spring Medical has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Zhonggeng Small Cap Value Stock holds 2.87 million shares, remaining unchanged, while Hong Kong Central Clearing Limited increased its holdings by 1.11 million shares to 2.29 million shares [3] - New shareholders include Ping An Low Carbon Economy Mixed A, which holds 1 million shares, while other funds have exited the top ten shareholder list [3]

Core Viewpoint - Spring Medical's stock closed at 23.99 yuan, up 6.39%, with a rolling PE ratio of 71.97, marking a new low in 379 days, and a total market capitalization of 9.202 billion yuan [1] Company Summary - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, PRP preparation kits, and negative pressure wound drainage kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - For Q1 2025, Spring Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, up 5.20%, with a gross profit margin of 66.69% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Spring Medical at the 92nd position in the industry ranking [1] - The total market capitalization of the industry averages 11.897 billion yuan, with the median at 5.767 billion yuan [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Spring Medical, which has a closing price of 22.55 yuan and a rolling PE ratio of 67.65 times, significantly higher than the industry average of 55.70 times [1][2] - Spring Medical's total market capitalization is reported at 8.649 billion yuan, with an increase in shareholder accounts to 7,167, reflecting a rise of 501 accounts [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] Group 2 - For the first quarter of 2025, Spring Medical achieved an operating revenue of 230 million yuan, representing a year-on-year growth of 3.60%, and a net profit of 58.0711 million yuan, with a year-on-year increase of 5.20% [1] - The gross profit margin for the company stands at 66.69%, indicating strong profitability within its operations [1] - The company has been recognized as a champion enterprise in the artificial joint prosthesis manufacturing sector by the Ministry of Industry and Information Technology in 2024 [1]

Core Viewpoint - Spring Medical (01858) has announced an investment in the Nanchang Defu Phase IV Equity Investment Fund Partnership, focusing on the healthcare industry, which aligns with the company's main business [1] Investment Details - The company will invest 50 million RMB, representing 9.2105% of the fund's total shares [1] - The investment targets growth and mature enterprises/projects in the healthcare sector [1] Strategic Implications - This investment aligns with the company's strategic development direction and enhances its industrial layout [1] - Collaboration with partners is expected to leverage investment experience and resource advantages, promoting deep integration of industrial operations and capital management [1] - The initiative aims to create a virtuous cycle of collaborative development, enhancing the company's core competitiveness and overall profitability [1] - The goal is to achieve sustainable, safe, healthy, and stable high-quality development for the company [1]

Core Viewpoint - Spring Medical (01858) announced an investment in the Nanchang Defu Phase IV Equity Investment Fund Partnership, focusing on growth and mature companies/projects in the healthcare industry, aligning with the company's strategic development direction [1] Investment Details - The company, as a limited partner, invested 50 million RMB, representing 9.2105% of the fund's total shares [1] - The investment aims to leverage the experience and resource advantages of the partners to enhance the company's operational and capital integration [1] Strategic Implications - The investment is expected to promote a virtuous cycle of collaborative development, enhancing the company's core competitiveness and overall profitability [1] - This move is aligned with the company's goal of achieving sustainable, safe, healthy, and stable high-quality development [1]

（ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司關於與私募基金合作投資的公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年8月7日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 ...

证券之星消息，截至2025年8月7日收盘，春立医疗(688236)报收于22.26元，上涨1.18%，换手率 1.01%，成交量2.9万手，成交额6522.79万元。 8月7日的资金流向数据方面，主力资金净流出2.75万元，占总成交额0.04%，游资资金净流入399.59万 元，占总成交额6.13%，散户资金净流出396.84万元，占总成交额6.08%。 近5日资金流向一览见下表： | 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 85.38亿元 | 116.92亿元 | 44 123 | | 净资产 | 28.79亿元 | 38.99亿元 | 52 123 | | 净利润 | 5807.11万元 | 7720.04万元 | 37 123 | | 市盈率(动) | 36.76 | 61.09 | 41 123 | | 市净率 | 2.98 | 3.85 | 64 123 | | 毛利率 | 66.69% | 51.31% | 28 123 | | 净利率 | 25.25% | 10.95% | 28 123 | | ROE | ...

截至2025年8月7日收盘，春立医疗股价报22.26元，较前一交易日上涨1.18%。当日成交量为29042手， 成交额达0.65亿元。 资金流向方面，8月7日主力资金净流出2.75万元，近五日主力资金累计净流出503.18万元。 风险提示：投资有风险，市场波动可能导致股价变动，投资者需谨慎决策。 来源：金融界 春立医疗主营业务为医疗器械的研发、生产和销售，所属板块包括医疗器械、专精特新等。公司产品涵 盖骨科植入物及配套手术器械，主要应用于关节、脊柱等领域的治疗。 消息面上，春立医疗8月7日公告称，公司以自有资金5000万元参与认购南昌德福四期股权投资基金合伙 企业份额，占基金总规模的9.2105%。该基金主要投资于医疗健康产业相关领域的成长期及成熟期企业 或项目，与公司主营业务具有协同性。 ...